According to current study findings, the guideline from ADA 2023 has designated SGLT-2i and GLP-1 RAs as first-line drugs for T2DM patients with established ASCVD or high cardiovascular risk, and metformin is no longer recommended as first-line therapy for T2DM patients with high cardiovascular risk due to its neutral HF benefits
Darstein M, Petralia RS, Swanson GT, Wenthold RJ, Heinemann SF
Symptoms, testing, and diagnosis Low carnitine can cause symptoms such as tiredness, muscle weakness, exercise intolerance, low muscle tone, poor feeding in infants, or episodes of low blood sugar
The Adobe CS6 software suite (Adobe, San Jose, CA, USA) was used for illustrations
doi: 10.1016/j.cmet.2013.04.008 21 ChegeniMHayesAMRGonzalezTDManderfeldMMLimJMenonRSet al
A similar finding in patients with COVID-19 was reported, with higher antibody titres against SARS-CoV-2 being associated with more severe disease 47